Open an account

Enlivex

ENLV · NASDAQ

$0.2237+$0.0163 (+7.86%)TodayMarket closed ·
Prev close $0.2074

About ENLV

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. The company is headquartered in Ness Ziona, Central(Hamerkaz) and currently employs 34 full-time employees. The company went IPO on 2014-07-30. The firm focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.

Employees
34
Headquarters
Ness Ziona, Central(HaMerkaz)
Listed
Jul 30, 2014
Sector
Health Care
Industry
Biotechnology
Website
enlivex.com

ENLV key statistics

Market cap
4.45M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.51M
Volume
447.51K
Open price
$0.215
High today
$0.229
Low today
$0.2051
52 Week high
$27.15
52 Week low
$0.1925

Enlivex (ENLV) at a glance

Enlivex (ENLV) last traded at $0.2237, with a market cap of 4.45M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.2051 and $0.229. The current price is 9.1% above the day's low and 2.3% below its high.

Volume so far is 447.51K shares, below the average of 2.51M shares a day.

Over the past year Enlivex has ranged from $0.1925 to $27.15, and now sits 0% of the way up that range.

Enlivex met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q4 FY25 it reported -$117.75 per share against an estimate of -$0.459.

The average analyst price target is $81.60, 36377.4% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 3 analystsAvg $81.60
Low
$80.80
Now
$0.2237
High
$84.00

ENLV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 27.1% on average.

  1. Q1 FY24: reported -$3.30 per share against an estimate of -$3.83
  2. Q2 FY24: reported -$2.40 per share against an estimate of -$2.30
  3. Q3 FY24: reported -$1.80 per share against an estimate of -$2.83
  4. Q4 FY24: reported -$3.45 per share against an estimate of -$2.37
  5. Q1 FY25: reported -$2.25 per share against an estimate of -$2.45
  6. Q2 FY25: reported -$1.20 per share against an estimate of -$2.45
  7. Q3 FY25: reported -$1.35 per share against an estimate of -$1.84
  8. Q4 FY25: reported -$117.75 per share against an estimate of -$0.459

ENLV news

  • Rishabh Mishra

    Stock Market: Will S&P 500 Open Up or Down Today?

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results

  • Avi Kapoor

    Dow Jumps 350 Points; Coca-Cola Shares Gain On Upbeat Earnings

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Vandana Singh

    Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum

  • Avi Kapoor

    Dow Jumps 300 Points; Waldencast Shares Plunge

Similar companies

Companies in the same industry as Enlivex

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.